EGFR and glioblastoma: In a large study including 418 patients with pathologically proven glioblastomas, Sohn et al.’s radiomics model demonstrated sensitivity of 81.2%, specificity of 58.5% and an AUC of 0.743 for EGFR amplification prediction [70].